Other languages AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
3.77 ^USD	-1.82%		-5.04%	-33.98%

11/03	AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases	MT
11/03	AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases	11/03
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions	11/03
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024	06/03
AbCellera Biologics Inc. Announces Board Changes	24/02
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
AbCellera Biologics, Inc. Announces Reduction in Workforce	29/11
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023	03/11
AbCellera Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
AbCellera Expands Antibody Discovery Collaboration With Regeneron	20/23/20
AbCellera Biologics Inc. Expands Multi-Target Antibody Discovery Collaboration with Regeneron	20/23/20
AbCellera Biologics Shares Rise After COO Stock Purchases Disclosed	15/23/15
AbCellera and Incyte to Collaborate on Therapeutic Antibody Development in Oncology	13/23/13
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology	13/23/13
AbCellera Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04
AbCellera Biologics Says Rehearing Request Against Microfluidic Devices Patent Denied	25/23/25
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera	15/23/15
DAMONA Pharmaceuticals Appoints John Reilly as Member of the Board of Directors	13/23/13
AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023	17/23/17
AbCellera Biologics Forms Partnership With RQ Bio for Infectious Disease Medicines	22/23/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Other languages

Filters